/Edwards%20Lifesciences%20Corp%20Irvine%2C%20Ca%20campus-by%20Steve%20Cukrov%20via%20Shutterstock.jpg)
Edwards Lifesciences Corporation (EW), headquartered in Irvine, California, provides products and technologies for structural heart disease and critical care monitoring. Valued at $48 billion by market cap, the company offers products such as tissue replacement heart valves, heart valve repair, hemodynamic monitoring devices, angioscopy equipment, oxygenators, and pharmaceuticals. The leading global structural heart innovation company is expected to announce its fiscal first-quarter earnings for 2026 in the near term.
Ahead of the event, analysts expect EW to report a profit of $0.72 per share on a diluted basis, up 12.5% from $0.64 per share in the year-ago quarter. The company beat the consensus estimates in three of the last four quarters while missing the forecast on another occasion.